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Abstract 
 
 
 
 
 
 
 
Erectile dysfunction (ED) is the inability to achieve and maintain an erection 
sufficient for satisfactory sexual intercourse. It is the most frequent sexual dysfunction in 
elderly men and its prevalence increases with age.  
Ever since ED was recognized as a real health problem, several treatment options 
became available and some of them proved to be very efficient. PDE5 inhibitors are the 
mainstay treatment of ED.  
However, other treatment options such as intracorporal injections, surgery, vacuum 
devices and prosthesis are also available for patients who are unresponsive to PDE5 
inhibitors. Since none of the treatment options available so far has proven ideal, research in 
the field of sexual medicine continues. The aim of this paper is to review the most advances 
in the treatment of ED. 
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Introduction 
Erectile dysfunction (ED) is the inability to 
achieve and maintain an erection sufficient for 
satisfactory sexual intercourse. It is the most 
frequent sexual dysfunction in elderly men and its 
prevalence increases with age. It has a worldwide 
occurrence. Studies show that approximately 52% 
of men aged 40-70 years old are affected to some 
degree by this disorder. While in young males, 
under the age of 40 years, ED was initially 
considered psychogenic, recent studies showed that 
in 14.8% of the cases the ED is organic (1-3). ED 
has a great impact on the patient's and his partner's 
quality of life as it can cause depression and anxiety 
and it can decrease emotional intimacy and 
satisfaction within a relationship (4).  
Penile erection is a complex neurovascular 
process which involves neurological, molecular, 
vascular, endocrine and psychological factors. 
Visual, olfactory and imaginary stimuli are also 
important. Sexual arousal releases neuro-
transmitters, especially nitric oxide (NO), from 
nonadrenergic-noncholinergic cavernous nerve 
terminals, through the action of NO-synthetize. NO 
activates guanylate cyclase which converts 
guanosine triphosphate to cyclic guanosine 
monophosphate which phosphorylates certain 
proteins and calcium channels, thus leading to 
inhibition of calcium channels, decrease in 
cytosolic calcium content and, in the end, 
vasodilatation and smooth muscle relaxation. As the 
blood fills the sinusoids, intracorporal pressure 
increases and the subtunical venules are 
compressed. The blood is trapped in the corpora 
cavernosa and the penis becomes erect (5-7).  
The most important risk factors for ED are 
aging, arterial hypertension, diabetes mellitus, 
atherosclerosis, hypercholesterolemia, smoking, 
prostatectomy, and drugs.  
 
Discussion 
Classification of ED  
ED can be classified as psychogenic, organic 
and mixed. Organic ED can be further classified as 
neurogenic, hormonal, vasculogenic, drug induced 
or related to systemic diseases. Mixed ED is the 
most common form of ED (6, 8).  
Psychogenic ED occurs more frequently in 
young men, under the age of 40 years. It can be 
associated with depression, performance anxiety, 
decreased self-esteem, stress in relationship, 
schizophrenia/ psychosis, lack of sexual 
arousability, and fear or shame of venereal or 
dermatological diseases. Compared to organic ED, 
psychogenic ED has a sudden onset, occurs in 
patients with psychological disorders or going 
through major life events, while spontaneous and 
self-stimulated erections are of good quality (6, 8, 
9).  
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Neurogenic ED is responsible for 10-19% of 
ED cases. Several neurogenic disorders have been 
associated with ED. Some patients with spinal cord 
injuries or perineal trauma do not respond to genital 
stimulation. Patients with stroke, Parkinson's 
disease and Alzheimer's disease have decreased 
libido and are not able to initiate the erectile 
process. ED is up to three times more frequent in 
patients with epilepsy. Multiple sclerosis is one of 
the most prevalent neurologic disorders occurring in 
young men and in 70% of cases it is associated with 
ED (3, 6, 10).  
Several hormones and endocrine disorders 
have been associated with ED. Klinefelter's 
syndrome, congenital and acquired 
hypogonadotropic hypogonadism are associated 
with androgen deficiency and decreased libido. 
Hyperprolactinemia results in secondary 
hypogonadotropic hypogonadism and ED. Patients 
with hyperthyroidism and hypothyroidism also have 
decreased erectile function (3, 6).  
Vascular disorders are also frequently 
responsible for ED. Adequate arterial inflow and 
venous outflow occlusion are both mandatory in 
order to achieve an erection. Hypertension, 
atherosclerosis, diabetes mellitus and trauma are 
associated with inadequate arterial inflow while 
veno-occlusive dysfunction is associated with 
venous leakage. Subclinical perineal trauma is also 
associated with ED and is probably determined by 
the occurrence of focal arterial occlusive disease. 
That is also the case in young men who bicycle 
more than 3 hours a week (3, 6, 11).  
ED can be induced by several drugs through 
various mechanisms. Antihypertensives like beta-
adrenergic blocking agents and thiazide diuretics, 
antiandrogens like finasteride, NSAIDs, 
antidepressants like selective serotonin anti-
reuptake inhibitors, anxiolytics and neuroleptics are 
some of the medications most frequently associated 
with ED (3).  
Systemic diseases like diabetes mellitus, 
chronic renal failure, multiple sclerosis, and 
generalized atherosclerotic disease can often lead to 
ED (6).  
Erectile dysfunction treatment  
Ever since ED was recognized as a real health 
problem, several treatment options became 
available and some of them proved very efficient. 
Lifestyle modifications, oral phosphodiesterase-5 
(PDE5) inhibitors, intracorporal injections, topical 
medication, surgery, vacuum devices, and 
acupuncture are only some of the treatments 
available today for ED. However, since all these 
treatments have limitations, the search for novel 
therapies continues (12, 13).  
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Lifestyle modifications  
Since ED and coronary artery disease share 
similar risk factors, it is easy to presume that the 
same lifestyle modifications required for cardiac 
disease should be required for ED. According to the 
European Association of Urology guidelines, 
lifestyle changes and risk factor management must 
precede or accompany any pharmacological 
treatment, patients with cardiac disease and diabetes 
mellitus having the greatest benefits from these 
changes (14, 15). Therefore, smoking cessation, 
weight loss, physical activity, avoiding stress and 
the use of alcohol and illicit drugs should be 
recommended to all patients suffering from ED (4).  
Gupta et. al performed a systematic review 
and meta-analysis of controlled trials assessing the 
effect of lifestyle changes and pharmacotherapy on 
ED. They included 740 participants from 4 
countries and concluded that pharmacotherapy for 
cardiovascular risk factors and lifestyle 
modifications are effective in patients with ED (16). 
Some authors suggest that administration of 
over the counter dietary supplements such as Panax 
ginseng may be beneficial to patients with ED, it is 
associated with low toxicity and low costs and, with 
a physician’s knowledge, could be included in ED 
treatment (17). 
Phosphodiesterase inhibitors (PDE)  
PDE inhibitors are the first-line treatment in 
patients with ED. Studies show that all PDE 
inhibitors are safe and effective, especially in men 
suffering from diabetes, multiple sclerosis, 
cardiovascular disease and spinal cord injury. PDE5 
is specific for to cGMP. It has an abundant 
expression in corpus cavernosum and determines 
degradation of cGMP. Inhibition of PDE5 leads to 
high levels of cGMP, muscle relaxation and, in the 
end, erection (18). 
Sildenafil was the first PDE inhibitor 
successfully used for the treatment of ED. Even 
though it is a selective PDE5 inhibitor, it cross-
reacts slightly with PDE6, which is mainly found in 
the retina. For that reason, some patients may 
experience visual disturbances like altered color 
perception and "star vision". The onset of action is 
30 minutes after the first dose and the half-life is 3-
5 hours. Studies show that 69% of patients taking 
sildenafil will obtain an erection suitable for sexual 
intercourse, as compared to only 22% of patients 
taking placebo (12, 18, 19).  
Vardenafil is a fast-acting selective PDE5-
inhibitor used for the treatment of ED. It has been 
used successfully in some patients who failed to 
respond to sildenafil. It has an onset of action of 10 
minutes and an average half-life of 4.2 hours. 
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Caution is advised in patients with prolonged QTc 
who are taking class 1 and class 3 antiarrhythmics 
(12, 18, 19).  
„Revitalise” was an international 
observational study which included 1832 patients 
with ED and metabolic syndrome from 10 countries 
who were treated with vardenafil. The aim of the 
study was to investigate the effectiveness and safety 
of vardenafil in the clinical setting. The authors 
report that 82.4% of the patients had an increase of 
at least 4 points in the IIEF-EF score and that after 
treatment 45.4% had normal erectile function. The 
authors therefore conclude that vardenafil is a good 
treatment option for patients with ED and metabolic 
syndrome (20).  
Tadalafil is a selective PDE5 inhibitor which 
showed no cross-reactivity with PDE6 but some 
cross-reactivity with PDE11. It is a safe drug which 
proved its effectiveness in ED occurring in both 
elderly and young men. It has an onset of 20 
minutes and the longest duration of action for this 
class of pro-erectile agents (up to 36 hours). It can 
be administered on demand or  administered daily, 
in small doses. Studies showed that 81% of patients 
treated with tadalafil were able to obtain an 
improvement in the erection quality, as compared to 
35% of patients in the placebo arm (12, 18, 19, 21).  
Avanafil was approved by the FDA in 2012. It 
is a potent competitive inhibitor of PDE5. It is a 
pyrimidine derivative which is rapidly absorbed and 
it reaches the maximum concentration in 30-45 
minutes (12, 18, 19). Cui et al. performed in 2014 a 
systematic review and meta-analysis in which they 
included 1381 patients from randomized controlled 
studies which compared avanafil with placebo. The 
authors concluded that patients treated with avanafil 
100 mg were more likely to achieve successful 
vaginal penetration and successful intercourse. The 
rate of discontinuation due to adverse events was 
similar in the two groups. Avanafil 100 mg seems 
to be as effective as avanafil 200 mg. The two 
concentrations seem to have similar safety profiles 
but headaches are more frequent in patients taking 
200 mg of avanafil (22).  
Udenafil is a PDE5 specific inhibitor 
developed in Korea for the treatment of ED. It also 
inhibits cGMP hydrolysis. It reaches peak plasma 
concentrations in 0.8-1.3 hours and is associated 
with rapid onset and a long duration. It is a well-
tolerated, safe, effective treatment for ED. It also 
proved its efficacy in patients with ED associated 
with diabetes mellitus, hypertension and lower 
urinary tract symptoms. It can be administered on 
demand or daily (12, 23).  
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Mirodenafil is another selective PDE5 
inhibitor developed in Korea for the treatment of 
ED. Its selectivity for PDE5 is 10 fold higher that 
sildenafil's selectivity for PDE5. It reaches the peak 
concentrations after 1.25 hours and it has a half-life 
of 2.5 hours. It has beneficial effects in patients 
with ED and lower urinary tract symptoms and 
benign prostatic hyperplasia. Daily treatment with 
mirodenafil and on demand treatment are both 
effective in patients with ED (12, 24).  
Testosterone replacement therapy (TRT)  
In the past, testosterone was believed to 
enhance sexual function in males. Currently, 
however, it has been shown that testosterone is only 
useful in males with hypogonadism. Hypogonadism 
usually affects older males and ED is one of its 
symptoms. Even though TRT has beneficial effects 
on several of the symptoms related to 
hypogonadism, data regarding its usefulness in ED 
is controversial. Some studies suggest that 
combining TRT with PDE5 inhibitors could be 
helpful in patients who are unresponsive to PDE5 
inhibitors alone. Randomized controlled studies are 
however necessary to support these observations 
(25, 26).  
Testosterone cypionate is available for 
intramuscular injections administered every three 
weeks. As an alternative, testosterone patches and 
gels are available for daily use (27).  
Alprostadil  
Alprostadil is a synthetic prostaglandin E1 
which has been approved for the treatment of ED. 
Intracavernous alprostadil injections are a second 
line treatment in ED. A study performed on 848 
men aged 18-75 years old treated with 
intracavernosal alprostadil showed that the 
treatment is effective in achieving satisfactory 
erections and safe (28). Fear of penile puncture and 
pain restrict the use of alprostadil injections.  
Alprostadil urethral suppositories are also a 
second line treatment in ED. They have the 
advantage of minimal adverse reaction and drug 
interactions but their efficacy is lower than that of 
alprostadil injections and patient compliance is low 
due to moderate to severe penile pain (6, 29, 30). 
Alprostadil cream is an alternative to urethral 
suppositories and injections. Rooney et. al 
performed a study in 2009 in which they aimed to 
evaluate the efficacy and safety of topical 
alprostadil. The study included 1161 patients with 
ED who were asked to administer 200 mcg to the 
penis meatus before intercourse for four weeks. 
After four weeks the patients were asked to apply 
300 mcg if hypo-responsive and 100 mcg if hyper-
responsive. The authors concluded that alprostadil 
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cream was effective and safe for the patients and 
their partners and the most frequent adverse events 
were limited to the application site (31).  
Other intracavernosal injections  
Apart from aprostadil, other substances can 
also be injected intracavernosally in patients who 
do not respond to oral treatment with PDE5 
inhibitors. 
Papaverine has multiple mechanisms of action 
which make it useful in ED. It is a non-specific 
PDE5 inhibitor; it decreases resistance to arterial 
inflow and increases resistance to venous outflow. 
Its utilization is however limited by its side effects: 
corporal fibrosis and priapism (6, 12).  
Phentolamine is a competitive α-adrenoceptor 
antagonist which can also determine histamine 
release from mast cells. It can decrease resistance to 
arterial flow. It is not very effective in 
monotherapy. It can cause hypotension and reflex 
tachycardia (6, 12).  
The vasoactive intestinal peptide (VIP) is a 
vasodilator that stimulates cAMP formation. It 
failed to prove its efficacy in ED when administered 
in monotherapy but showed some good results 
when it was administered with phentolamine (12). 
While the efficacy of this class of agents in 
monotherapy is not very high, when used in 
combination they act synergistically and are 
associated with a response rate of up to 90%. The 
most frequent and effective combination includes 
papaverine, phentolamine and alprostadil (6, 12). 
Stem cells  
Stem cells (SC) are intensely studied at 
present, especially for the treatment of neurogenic 
ED where available therapies are not very effective. 
SC can differentiate into endothelial cell, neurons, 
smooth muscle cells and Schwann cells, among 
others, and there is hope that once transplanted they 
might help the regeneration of the injured tissue.  
Three types of SC are generally used in ED: 
adipose tissue-derived SC (ADSC), muscle-derived 
SC (MDSC) and bone-marrow derived SC 
(BMSC). The SC can be delivered by intravenous 
injection, intracorporal injection or intraperitoneal 
injection.  
Studies involving SC were performed on 
animal models, especially rats, and have shown 
promising results. Since stem cells might provide a 
cure for ED and not only symptom relief, the results 
of clinical trials on men with ED are 
enthusiastically awaited (13, 32, 33).  
Vacuum erection devices (VED)  
Even though VED can be used for the 
treatment of ED of any etiology and have been 
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recommended by the American Urological 
Association as an alternative therapy since 1998, 
they only became more frequently used in the last 
years, especially in patients requiring penile 
rehabilitation after radical prostatectomy.  
VED produce negative pressure with the help 
of a vacuum pump. This causes the distension of the 
corporal sinusoids and arterial blood inflow. A 
constriction ring is placed at the base of the penis to 
decrease venous outflow. As a result, the penis 
becomes erect. In patients with ED due to radical 
prostatectomy, VED help the recovery of erectile 
function through anti-hypoxic, anti-apoptosis and 
anti-fibrotic mechanisms. Some authors suggest that 
when VED are used for penile rehabilitation, the 
rubber ring should not be used, as it may lead to 
fibrosis as a result of prolonged ischemia and 
acidosis.  
Studies show that VED are effective in up to 
90% of patients. They allow sexual intercourse soon 
after surgery and result in early return of natural 
erections. 
VED are non-invasive treatment methods and 
the most commonly reported adverse reactions are 
bruising, pain, cold penis or penile discomfort. 
Caution is required in patients undergoing 
anticoagulant treatment (10, 34-37).  
Surgical management  
Surgical treatment is rarely necessary in 
patients with ED and it is reserved for patients who 
are resistant to PDE5 inhibitors.  
Arterial revascularization has been tried in 
patients with penile artery insufficiency of various 
causes but it mostly benefits young men with 
traumatic disruption of the vasculature. Several 
technics are available but most commonly the 
epigastric artery is anastomosed to the dorsal penile 
artery. The revascularization technique is only 
effective in 30-50% of cases (6).  
More recently, endovascular treatments were 
tried in patients with vasculogenic ED refractory to 
PDE5 inhibitors. The Zen Trial (Zotarolimus-
Eluting Peripheral Stent System for the Treatment 
of ED in Males with Sub-Optimal Response to 
PDE5 Inhibitors) published in 2012 investigated the 
use of drug-eluting stents in patients with focal 
atherosclerotic lesions of the internal pudendal 
artery. The drug they used was zotarolimus, an 
immunosuppressive agent which prevents restenosis 
and the rate of neointimalization. Even though the 
authors obtained some promising results, larger 
studies are necessary to support the usefulness of 
the technique (11, 37, 38).  
Venous surgery should only be performed in 
patients with proven venous leakage who have a 
normal arterial response on duplex Doppler and 
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who do not have generalized penile venous disease. 
Surgical ligation of the deep dorsal vein and its 
collaterals was used in the past but only showed 
positive results in approximately 25% of patients (6, 
11).  
In 2013 Aschenbach et. al performed a study 
on 29 patients with ED due to veno-occlusive 
dysfunction who were treated with endovascular 
embolization therapy with N-butyl-2-cyanoacrylate. 
The procedure was performed under local 
anesthesia, it was minimally invasive and clinical 
success was achieved in 88,8% of the patients (39).  
Prosthetic surgery is the third-line treatment in 
patients with ED and is only recommended in 
patients who have failed or refused other 
treatments. Patients must be aware that prosthesis 
surgery is irreversible and physiologic erections 
will not be possible any more. Two types of 
prostheses are available: non-inflatable and 
inflatable. Non inflatable prostheses have the 
advantage of being more durable and cheaper and 
the disadvantages of causing permanent erection, 
and they are difficult to conceal and device erosion 
can occur. Inflatable prostheses have the advantage 
that they offer a flaccid state and an erect state and 
the disadvantage that mechanical failure can occur. 
Infections are the most important adverse reactions. 
The long-term satisfaction rate is very high in 
patients using inflatable and non-inflatable 
prostheses. This procedure however is only 
recommended to select patients who are willing to 
undergo implantation of a penile prosthesis (6, 40-
42).  
Other treatment options  
Several devices have been produced in the last 
years for the treatment of ED. External support 
devices such as penile casts, vibrators, low intensity 
extracorporeal shockwave, impulse magnetic field 
therapy or tissue engineering are just some of the 
novel devices and procedures proposed for the 
treatment of ED. Further studies are necessary to 
prove the efficacy of those devices and procedures. 
However, there are high hopes that some of them 
might complete the therapeutic arsenal of ED (37).  
 
Conclusions  
ED is a frequent sexual dysfunction which 
affects men worldwide and has a great impact on 
the patient's and his partner's quality of life. PDE5 
inhibitors are the mainstay treatment of ED. Several 
other treatment options such as intracorporal 
injections, surgery, vacuum devices and prosthesis 
are however available for patients who are 
unresponsive to PDE5 inhibitors. Since none of the 
treatment options available so far proved ideal, 
research in the field of sexual medicine continues.  
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